Trial abstract · §3
TB4-PH2-VENOUSULCER — results
Primary endpoint, absolute and relative effect where derivable, and harms as reported.
§3Results
§3.1Primary endpoint
Table 3. Primary endpoint as reported.
| Endpoint | Result as reported | Certainty |
|---|---|---|
| Time to complete healing of a venous stasis ulcer | A signal in a small sample; not confirmed in a larger trial | Low |
| Reproduced from the published report. Where the report states a confidence interval the Institute reproduces it; where it does not, none is constructed. | ||
§3.2Endpoint hierarchy
§3.3Harms as reported
Table 5. Adverse events for Thymosin beta-4 from the safety tables the Institute holds for this compound. Where a row names a different trial as its source, the figure is from that trial and not from this one.
| Event | Active, % | Comparator, % | Source trial |
|---|---|---|---|
| Injection-site reaction | — | — | Reported |
| No dose-limiting toxicity in phase 1 | — | — | Reported at the doses studied |
| Angiogenic mechanism | — | — | Neoplasia implications unstudied over long exposure |
Compound Evidence Institute · CEI-TR-0113/3 · https://compoundevidence.com/trials/tb4-ph2-venousulcer/results/ · retrieved 30 July 2026